UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Jan

    11

    Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases

    Read More

    Jan

    03

    ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

    Read More

    Dec

    02

    UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

    Read More

    Dec

    01

    Media Statement on levetiracetam (KEPPRA® and KEPPRA XR®) and DRESS

    Read More

    Nov

    17

    Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate

    Read More

    Nov

    14

    UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

    Read More

    Nov

    10

    UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

    Read More

    Nov

    09

    Advancing Rheumatic Disease Treatment

    Read More

    Nov

    01

    UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

    Read More

    Oct

    31

    NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

    Read More